Rockwell Medical Management
Management criteria checks 2/4
Rockwell Medical's CEO is Mark Strobeck, appointed in Jul 2022, has a tenure of 2.42 years. total yearly compensation is $1.05M, comprised of 53.7% salary and 46.3% bonuses, including company stock and options. directly owns 0.06% of the company’s shares, worth $40.50K. The average tenure of the management team and the board of directors is 2.3 years and 4.5 years respectively.
Key information
Mark Strobeck
Chief executive officer
US$1.1m
Total compensation
CEO salary percentage | 53.7% |
CEO tenure | 2.4yrs |
CEO ownership | 0.06% |
Management average tenure | 2.3yrs |
Board average tenure | 4.5yrs |
Recent management updates
Recent updates
Rockwell Medical, Inc.'s (NASDAQ:RMTI) 28% Dip In Price Shows Sentiment Is Matching Revenues
Nov 15Rockwell Medical, Inc. (NASDAQ:RMTI) Analysts Just Trimmed Their Revenue Forecasts By 15%
Nov 14The Market Lifts Rockwell Medical, Inc. (NASDAQ:RMTI) Shares 28% But It Can Do More
Sep 29Rockwell Medical: The Turnaround Is Looking Real
Sep 15Rockwell Medical, Inc. Just Reported A Surprise Profit And Analysts Updated Their Estimates
Aug 11Rockwell Medical, Inc.'s (NASDAQ:RMTI) Subdued P/S Might Signal An Opportunity
Jul 12Does Rockwell Medical (NASDAQ:RMTI) Have A Healthy Balance Sheet?
May 08Is Rockwell Medical (NASDAQ:RMTI) A Risky Investment?
Feb 06Rockwell Medical, Inc. (NASDAQ:RMTI) Doing What It Can To Lift Shares
Dec 25Is Rockwell Medical (NASDAQ:RMTI) Using Too Much Debt?
Oct 11Is Rockwell Medical (NASDAQ:RMTI) Weighed On By Its Debt Load?
Jun 02Is There Now An Opportunity In Rockwell Medical, Inc. (NASDAQ:RMTI)?
Oct 25An Intrinsic Calculation For Rockwell Medical, Inc. (NASDAQ:RMTI) Suggests It's 46% Undervalued
Sep 02Rockwell Medical Q2 Earnings Preview
Aug 12Rockwell Medical: Triferic Remains Key Despite Sluggish Growth Profile
Mar 02Rockwell Medical: Down But By No Means Out
Oct 05CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Sep 30 2024 | n/a | n/a | -US$1m |
Jun 30 2024 | n/a | n/a | -US$5m |
Mar 31 2024 | n/a | n/a | -US$9m |
Dec 31 2023 | US$1m | US$566k | -US$9m |
Sep 30 2023 | n/a | n/a | -US$9m |
Jun 30 2023 | n/a | n/a | -US$12m |
Mar 31 2023 | n/a | n/a | -US$13m |
Dec 31 2022 | US$978k | US$267k | -US$19m |
Compensation vs Market: Mark's total compensation ($USD1.05M) is above average for companies of similar size in the US market ($USD654.40K).
Compensation vs Earnings: Mark's compensation has increased whilst the company is unprofitable.
CEO
Mark Strobeck (53 yo)
2.4yrs
Tenure
US$1,054,169
Compensation
Dr. Mark Strobeck, Ph D., serves as Independent Director at Windtree Therapeutics, Inc. since June 2023 and is its Lead Independent Director since August 13, 2024. He has served as the President, Chief Exe...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | 2.4yrs | US$1.05m | 0.060% $ 40.5k | |
Chief Financial Officer | 1.2yrs | US$453.18k | no data | |
Executive VP | 3.3yrs | US$660.29k | 0.034% $ 23.1k | |
Senior VP & Chief Commercial Officer | less than a year | no data | 0.028% $ 18.7k | |
Senior VP & Chief Corporate Affairs Officer | 2.3yrs | no data | no data |
2.3yrs
Average Tenure
51yo
Average Age
Experienced Management: RMTI's management team is considered experienced (2.3 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | 2.4yrs | US$1.05m | 0.060% $ 40.5k | |
Independent Director | 7.3yrs | US$142.27k | 0.11% $ 72.0k | |
Independent Chairman | 4.8yrs | US$170.00k | 0.10% $ 68.0k | |
Independent Director | 4.5yrs | US$127.94k | 0.098% $ 66.1k | |
Independent Director | 1.2yrs | US$89.51k | 0.0062% $ 4.2k | |
Independent Director | 7.5yrs | US$128.29k | 0.27% $ 182.2k | |
Independent Director | 4yrs | US$130.56k | 0.097% $ 65.0k |
4.5yrs
Average Tenure
61yo
Average Age
Experienced Board: RMTI's board of directors are considered experienced (4.5 years average tenure).
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/22 10:01 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Rockwell Medical, Inc. is covered by 16 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Tazeen Ahmad | BofA Global Research |
Jonathan Aschoff | Brean Capital |
Ritu Baral | Canaccord Genuity |